NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics

by Ed Johnson
March 3, 2021
A A

SANTA CLARA, Calif., March 02, 2021

Highlights:

  • Resolution Bioscience is a fast-growing, innovative leader in next-generation sequencing (NGS)-based oncology solutions.
  • Combination brings together Resolution Bioscience’s noninvasive liquid biopsy platform that improves cancer diagnostics with Agilent’s leadership in tissue-based companion diagnostics and global commercial and regulatory scale.
  • Furthers Agilent’s participation in fast-growing NGS technologies for precision oncology, expanding Agilent’s addressable market by $3 billion in 2025 with that figure estimated to double by 2030.

Agilent Technologies Inc. (NYSE: A), today announced it has entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions. The acquisition complements and expands Agilent’s capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market. Under the terms of the agreement, Agilent will pay $550 million in cash at closing and up to an additional $145 million based on achieving future performance milestones. 

Resolution Bioscience’s noninvasive liquid biopsy assay platform supports both the biopharma services market and the clinical oncology diagnostic testing market and is enabled by its Clinical Laboratory Improvement Amendments (CLIA)-certified lab. The platform has been designed for both a centralized CLIA test service and a distributable kit format. In addition, the Resolution Bioscience homologous recombination deficiency (HRD) assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration. The assay is performed on a standard blood sample and detects actionable mutations in genes for identifying cancer. Last year, Resolution Bioscience announced a commercial partnership with LabCorp to enable broad access to the Resolution ctDx Lung™ test that detects actionable mutations in genes associated with non-small cell lung cancer.

“We are extremely pleased to add Resolution Bioscience’s outstanding team and powerful technology to Agilent’s growing business in precision oncology solutions,” said Mike McMullen, Agilent president and CEO. “By adding Resolution Bioscience’s liquid biopsy-based diagnostic technologies to our portfolio, we are strengthening Agilent’s offering to our biopharma customers and boosting the growth of our diagnostics and genomics business. This also accelerates our strategy to broaden access to precision oncology testing for patients worldwide through distributed NGS-based diagnostic kits. We look forward to Resolution Bioscience joining with us to expand our work in the fight against cancer.”

“Agilent’s broad expertise, global regulatory and commercial infrastructure, extensive partnerships with biopharma companies, and decades-long leadership in precision medicine will enhance and accelerate our groundbreaking work,” said Mark Li, Resolution Bioscience president and CEO. “We are excited to further expand the use of NGS in precision oncology for clinical diagnostics as part of the Agilent team.”

Resolution Bioscience is based in Kirkland, Washington. The company had revenues of approximately $35 million in calendar year 2020 and is expected to generate $50 million to $55 million in revenue this year. The acquisition is expected to be slightly dilutive to Agilent’s non-GAAP earnings per share in fiscal 2021 and 2022, and improving in the following years.

The transaction is expected to close in April, subject to regulatory approvals and customary closing conditions. 

Tags: < Invest | M&A
ShareTweetShareSend

Related Industries

Healthcare

Bayer Announces Changes to U.S. Country Leadership Team

June 9, 2023
Healthcare

Cardinal Health announces the merger of its Outcomes™ business into Transaction Data Systems and related partnership

June 6, 2023
Healthcare

Medtronic names Ken Washington new Chief Technology and Innovation Officer

June 2, 2023
Healthcare

BD Names Laura Boros President of Pharmaceutical Systems

June 2, 2023
Healthcare

Medtronic to acquire wearable insulin patch maker EOFlow

May 26, 2023
Healthcare

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023

Cardinal Health announces the merger of its Outcomes™ business into Transaction Data Systems and related partnership

June 6, 2023

...

Apple’s Worldwide Developers Conference to kick off June 5, 2023, with keynote address

May 24, 2023

...

Honeywell Unveils Honeywell Forge For Buildings And Expands Sustainability-Focused Applications

May 26, 2023

...

Dow and New Energy Blue to develop renewable plastic materials from corn residue.

Dow and New Energy Blue announce collaboration to develop renewable plastic materials from corn residue

May 26, 2023

...

Stellantis Invests in Lyten’s Breakthrough Lithium-Sulfur EV Battery Technology

May 26, 2023

...

Dow’s Seadrift, Texas location selected for X-energy advanced SMR nuclear project to deliver safe, reliable, zero carbon emissions power and steam production

May 12, 2023

...

HP Inc. Appoints Glenn Williams as Chief Diversity Officer

May 10, 2023

...

Whirlpool Corporation Named One of the Best Companies to Work For in 2023 by U.S. News & World Report

June 7, 2023

...

Jolyon Bulley to become Americas CEO following Elie Maalouf’s appointment to Group CEO

May 18, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.